undamentalytics Newsletter
Sign in

Scienture Holdings, Inc. (SCNX) stock

Add to watchlist

Add holding +

NASDAQ: SCNX Nasdaq Pharmaceuticals Next results ~January 11, 2027

C Fundamentals grade

Scienture Holdings, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

Not valued: the figures our models need are missing or failed our data-quality checks.

Price vs value

No model value: free cash flow after stock pay is not positive. How we value companies.

Scienture Holdings, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds9 adding, 6 cuttingOf 1 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Scienture Holdings files

Where Scienture stands after its latest 10-Q

Scienture has little or no product revenue yet; it used $16m of cash in the twelve months to June 2026. That growth ranks 1 of 47 among the pharmaceuticals companies we cover. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 1 of our 3 financial-health checks.

Our models give no value for Scienture Holdings at present, so past values are not shown.

Source: 10-Q filed August 13, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 11, 2027 (estimated)

Scienture Holdings, Inc.'s trailing-twelve-month revenue grew 540.6% year on year, with a free-cash-flow margin of -1929.5%. Where it stands out: revenue growth of 540.6% ranks 1 of 74 pharmaceuticals companies we cover. Where it lags: net margin of -4620.9% ranks 72 of 75 pharmaceuticals companies we cover.

Current signal Revenue growth accelerating: TTM revenue growth rose to 540.6% (+315.5pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 540.6% over the last 12 months, against a median of 10.0% for pharmaceuticals companies we cover.
  • Growth speeding up. The growth rate is 315.5 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 7945.9 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Loss-making. Operating margin is -4878.9%: costs exceed revenue.
  • Burning cash. Free cash flow was -1929.5% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 257.1% of revenue, against a median of 3.6% for pharmaceuticals companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 2.1% in a year.
  • High sales multiple. The shares trade at 116 times revenue while operating margins remain thin.
  • Volatile shares. Over the past year the shares showed annualised volatility of 98% and a beta of 1.6 against the S&P 500.

Latest results: FY2026 Q2

Filed August 13, 2026
Earnings per share
-$1.75 against an average estimate of -$2.25: beat by 22.2%
Revenue
$0m
Share reaction
-9.2% in the first session after the results on October 19, 2026, against +0.8% for the S&P 500

Scienture Holdings' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.3%
  • 1 week+10.2%
  • 1 month-18.7%
  • This year-74.7%
  • 1 year-83.4%
  • 5 years-99.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$821,315
Operating margin
-4878.9%
Net margin
-4620.9%
EPS (TTM, diluted)
$-1.29

Growth

Revenue growth
+540.6%
Change in growth rate
+315.5 pts

Cash

Free cash flow (TTM)
-$15.8M
FCF margin
-1929.5%
Stock pay % of revenue
257.1%

Earnings

Last results
October 19, 2026
Next results (est.)
January 11, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Announcement
  3. Announcement
  4. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Scienture Holdings, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

Valuation models

We value Scienture Holdings, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 12.1%: the 10-year Treasury yield (4.9%) plus a beta of 1.6 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — 0 Does not apply: no positive value
Combined value Weighted average of the models that apply: the primary model (revenue-to-maturity model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Scienture Holdings, Inc. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$1541.85$644.77$630.76$420.50$1541.85$1235.81$551.33$94.15$80.92$151.25$12.75$3.23
Market value$17.2bn$7.2bn$7.6bn$5.2bn$19.5bn$20.3bn$9.6bn$1.7bn$1.5bn$4.4bn$391m$95m
+ Net debt (− = net cash)$156292$553287$493189−$347505−$3m−$6m−$3m−$594894$7m$5m−$5m−$8m
Enterprise value$17.2bn$7.2bn$7.6bn$5.2bn$19.5bn$20.3bn$9.6bn$1.7bn$1.5bn$4.4bn$387m$87m
Multiples
Price / sales n/mn/mn/mn/mn/mn/mn/m166.5xn/mn/mn/m116.1x
Price / earnings ——n/mn/m—————n/m——
Price / free cash flow ————————————
EV / EBITDA ——n/m—n/m———————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

29 /100

Weak moat

How hard Scienture Holdings's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -33.6% of total assets over 10 years.

  • Pricing power 12 / 20

    Gross margin has been a median 64.6%, moving by 28.0 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -26.3%; its worst year was -12824.7%.

  • Cash conversion 2 / 20

    Free cash flow was positive in 2 of 9 years, at a median -29.4% of revenue.

  • Discipline 10 / 20

    The diluted share count rose 1267.4% over five years; stock-based pay has been a median 2.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (34 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$4.44 — $4m +743%
Next −$0.27 +94% $15m +325%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −40.8% on 90 days ago. In the last 30 days, 1 analyst raised Scienture Holdings, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Scienture Holdings, Inc., last 90 days
−$8.00 −$6.00 −$4.00 −$2.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$7.50 Current fiscal year, 60 days ago: −$5.75 Current fiscal year, 30 days ago: −$5.75 Current fiscal year, 7 days ago: −$5.75 Current fiscal year, Now: −$4.44 −$4.44

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal year
90 days ago −$7.50
60 days ago −$5.75
30 days ago −$5.75
7 days ago −$5.75
Now −$4.44

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$2.25 −$1.75 +22.2%
Mar 2026 −$5.50 −$2.00 +63.6%
Dec 2025 −$7.00 −$3.17 +54.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

1 analysts, Oct 2026
Buy1100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202611
  2. Sep 202611
  3. Aug 202611

Counts of recommendations published by analysts covering Scienture Holdings, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
8.0%
of tradable shares
Days to cover
0.28
at average volume
Short interest, 1 month
+112%
to October 15, 2026
Held by institutions
5%
of shares
Held by insiders
22.1%
of shares
Employees
4
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
SCNX−55%−83%−14%+87%−92%−75%
Industry peers (median)−18%−49%−14%−2%+9%−12%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
SCNX42%25%42%33%17%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
SCNX−70%−90%−70%−75%−92%−80%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 3, 2015: 100% from February 11, 2020 to October 22, 2026. Getting back needed a 83394% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$2.77 – $20.45
From 52-week high
−84.2%
vs 50-day average
−47.6%
vs 200-day average
−64.6%
Volatility (1 year)
98%
Beta vs S&P 500
1.56

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
1 up, 11 down
typical move ±8.8%
After a week
0 up, 12 down
typical move ±12.7%
After a month
1 up, 10 down
typical move ±22.3%
Results releasedNext dayS&P 500 next day5 days21 days
October 19, 2026 −9.2% +0.8% −12.8% —
August 20, 2026 −5.1% −0.4% −19.8% −35.7%
May 22, 2026 0.0% +1.1% −1.0% −8.0%
May 15, 2023 −14.1% −0.3% −23.2% −20.6%
March 27, 2023 −16.3% 0.0% −34.9% −25.3%
November 7, 2022 −7.6% +1.5% −12.1% −47.4%
July 25, 2022 −3.0% −1.1% −6.6% −21.0%
May 9, 2022 −10.2% −3.0% −19.1% +4.5%
March 28, 2022 +14.9% +2.0% −3.1% −22.8%
October 25, 2021 −2.3% +0.6% −0.5% −20.2%
July 26, 2021 −14.4% −0.2% −5.3% −10.6%
April 26, 2021 −8.9% +0.2% −13.6% −29.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Scienture Holdings, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Scienture Holdings, Inc.
$0 $5M $10M $15M FY22 Q3 FY23 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY22 Q3: $11M Revenue (TTM), FY22 Q4: $10.8M Revenue (TTM), FY23 Q1: $8.1M Revenue (TTM), FY23 Q2: $5.2M Revenue (TTM), FY23 Q3: $3.5M Revenue (TTM), FY23 Q4: $1.4M Revenue (TTM), FY25 Q1: $146.9K Revenue (TTM), FY25 Q2: $128.2K Revenue (TTM), FY25 Q3: $653.4K Revenue (TTM), FY25 Q4: $431.6K Revenue (TTM), FY26 Q1: $477.7K Revenue (TTM), FY26 Q2: $821.3K $821.3K

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY22 Q3 $11M
FY22 Q4 $10.8M
FY23 Q1 $8.1M
FY23 Q2 $5.2M
FY23 Q3 $3.5M
FY23 Q4 $1.4M
FY25 Q1 $146.9K
FY25 Q2 $128.2K
FY25 Q3 $653.4K
FY25 Q4 $431.6K
FY26 Q1 $477.7K
FY26 Q2 $821.3K
Revenue growth, TTM YoY Scienture Holdings, Inc.
-200% 0% 200% 400% 600% FY21 Q3 FY22 Q2 FY23 Q1 FY26 Q2 Revenue growth, TTM YoY, FY21 Q3: -43.6% Revenue growth, TTM YoY, FY21 Q4: -42.2% Revenue growth, TTM YoY, FY22 Q1: -43.9% Revenue growth, TTM YoY, FY22 Q2: -13.7% Revenue growth, TTM YoY, FY22 Q3: 15.4% Revenue growth, TTM YoY, FY22 Q4: 9.5% Revenue growth, TTM YoY, FY23 Q1: -19.8% Revenue growth, TTM YoY, FY23 Q2: -54.9% Revenue growth, TTM YoY, FY23 Q3: -68.0% Revenue growth, TTM YoY, FY23 Q4: -87.3% Revenue growth, TTM YoY, FY26 Q1: 225.2% Revenue growth, TTM YoY, FY26 Q2: 540.6% 540.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY21 Q3 -43.6%
FY21 Q4 -42.2%
FY22 Q1 -43.9%
FY22 Q2 -13.7%
FY22 Q3 15.4%
FY22 Q4 9.5%
FY23 Q1 -19.8%
FY23 Q2 -54.9%
FY23 Q3 -68.0%
FY23 Q4 -87.3%
FY26 Q1 225.2%
FY26 Q2 540.6%
Operating margin (TTM) Scienture Holdings, Inc.
-15000% -10000% -5000% 0% FY22 Q3 FY23 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY22 Q3: -28.0% Operating margin (TTM), FY22 Q4: -31.0% Operating margin (TTM), FY23 Q1: -39.5% Operating margin (TTM), FY23 Q2: -52.0% Operating margin (TTM), FY23 Q3: -92.1% Operating margin (TTM), FY23 Q4: -320.2% Operating margin (TTM), FY25 Q1: -8699.3% Operating margin (TTM), FY25 Q2: -12824.7% Operating margin (TTM), FY25 Q3: -2648.5% Operating margin (TTM), FY25 Q4: -9867.9% Operating margin (TTM), FY26 Q1: -8903.3% Operating margin (TTM), FY26 Q2: -4878.9% -4878.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY22 Q3 -28.0%
FY22 Q4 -31.0%
FY23 Q1 -39.5%
FY23 Q2 -52.0%
FY23 Q3 -92.1%
FY23 Q4 -320.2%
FY25 Q1 -8699.3%
FY25 Q2 -12824.7%
FY25 Q3 -2648.5%
FY25 Q4 -9867.9%
FY26 Q1 -8903.3%
FY26 Q2 -4878.9%
FCF margin (TTM) Scienture Holdings, Inc.
-15000% -10000% -5000% 0% 5000% FY22 Q3 FY23 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY22 Q3: -29.2% FCF margin (TTM), FY22 Q4: -14.2% FCF margin (TTM), FY23 Q1: -18.2% FCF margin (TTM), FY23 Q2: 0.8% FCF margin (TTM), FY23 Q3: 0.4% FCF margin (TTM), FY23 Q4: -162.6% FCF margin (TTM), FY25 Q1: -4788.3% FCF margin (TTM), FY25 Q2: -10366.6% FCF margin (TTM), FY25 Q3: -1701.2% FCF margin (TTM), FY25 Q4: -3213.9% FCF margin (TTM), FY26 Q1: -2991.2% FCF margin (TTM), FY26 Q2: -1929.5% -1929.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY22 Q3 -29.2%
FY22 Q4 -14.2%
FY23 Q1 -18.2%
FY23 Q2 0.8%
FY23 Q3 0.4%
FY23 Q4 -162.6%
FY25 Q1 -4788.3%
FY25 Q2 -10366.6%
FY25 Q3 -1701.2%
FY25 Q4 -3213.9%
FY26 Q1 -2991.2%
FY26 Q2 -1929.5%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 1 1 3 2 3 4 7 17 10 10 1 0 0 1
Gross profit 0 1 3 2 3 3 5 6 5 6 0 0 0 1
EBITDA −2 −1 −0 −1 0 — 0 −3 −5 −3 −4 −15 −42 −39
Operating income −2 −1 −0 −1 0 −0 0 −3 −5 −3 −4 −15 −43 −40
Net income −2 −2 −1 −3 0 0 −0 −3 −5 −3 −18 9 −42 −38
Diluted EPS −$0.21 −$0.01 −$0.11 −$0.02 $0.00 $0.00 −$0.02 −$0.01 −$0.02 −$0.19 −$2.92 $0.31 −$1.35 −$1.29
Growth (year on year)
Revenue — +56.5% +94.7% −14.8% +18.1% +30.7% +94.1% +130.3% −42.2% +3.6% −86.7% −90.0% +215.9% +540.6%
Operating income — — — — — −122.2% — — — — — — — —
Net income — — — — — −96.9% — — — — — — −557.9% —
Diluted EPS — — — — — −100.0% — — — — — — −535.5% —
Margins
Gross margin 1.2% 70.6% 93.5% 100.0% 100.0% 88.3% 65.5% 33.3% 48.0% 53.8% 3.6% 4.4% 76.8% 87.7%
EBITDA margin −217.6% −95.4% −4.6% −40.6% 13.9% — 1.8% −14.6% −53.4% −28.3% −320.9% <−999% <−999% <−999%
Operating margin −218.0% −95.7% −4.7% −40.6% 13.5% −2.3% 1.7% −14.6% −53.5% −28.4% −322.4% <−999% <−999% <−999%
Net margin −218.8% −134.5% −38.4% −111.2% 9.9% 0.2% −3.8% −14.8% −53.8% −33.9% <−999% >999% <−999% <−999%
Free-cash-flow margin −89.5% — — — — — — −13.2% −26.2% — — <−999% <−999% —
Cash flow
Cash from operations −1 −1 0 −1 0 0 0 −2 −3 −2 −2 −14 −13 −14
Capital spending 0 — — — — — — 0 0 — — 0 0 —
Free cash flow −1 — — — — — — −2 −3 — — −14 −13 —
Stock-based pay — 1 0 — — — 0 0 0 0 0 0 2 2
Free cash flow after stock pay — — — — — — — −3 −3 — — −14 −15 —
Balance sheet
Cash 0 1 0 0 0 1 3 6 3 1 0 0 7 8
Total debt 0 0 0 1 1 1 0 — 0 1 7 6 2 —
Net debt (negative = net cash) −0 −1 0 1 0 −0 −3 −6 −3 −1 7 5 −5 −8
Diluted shares 10m 11m 11m 11m 12m 12m 13m 16m 17m 18m 19m 29m 31m 30m
Returned to shareholders
Dividends — — — — — — — — — — — 15 — —
Total returned — — — — — — — — — — — 15 — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 3 checks passed · June 30, 2026
What it owns · $88m
Short-term assets $9mLonger-term assets $79m
What it owes, and who funded it · $88m
Short-term liabilities $3mLonger-term liabilities $21mShareholders' equity $64m
  • Short-term assets cover short-term liabilities $9m of assets due within a year against $3m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $9m short-term assets against $21m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$40m against $3m of interest.

From Scienture Holdings, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
304.2%
of revenue
Days sales outstanding
171 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated SCNX SXTP SXTC LPCN NTRB AKAN Median
Revenue, last 12 months $821315 $1m $1m $2m $2m $258075 $276m
Revenue growth, last 12 months 540.6% 73.2% −34.6% −62.7% −37.3% −69.2% 9.9%
Revenue growth, 3-year average −58.5% 74.9% — 205.6% −10.8% — 5.5%
Revenue growth, latest quarter 449.1% 106.0% — −69.5% −29.7% — 6.5%
Gross margin 87.7% 19.4% 21.9% — 33.1% −60.5% 62.0%
Operating margin <−999% −774.9% −625.9% −800.8% −435.6% <−999% −5.9%
Operating margin, 3-year average <−999% <−999% −267.4% −378.5% −396.6% — −7.4%
Net margin <−999% −729.9% −545.2% −755.1% −430.4% −467.1% −7.3%
Cash from operations / revenue <−999% −789.8% −353.0% −713.0% −224.5% <−999% 10.2%
Free-cash-flow margin <−999% −800.6% −353.0% −713.0% −224.5% <−999% 8.6%
Free-cash-flow margin, 3-year average <−999% — −126.6% −309.9% −217.5% — 7.4%
Stock pay / revenue 257.1% 37.2% 466.2% 14.6% 65.9% 21.3% 3.6%
Change in share count 2.1% — >999% 25.2% 8.9% −93.4% 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth 540.6% 10.0% 1 of 74
Change in growth rate Growth +315.5pp -0.3pp 1 of 74
Gross margin Profitability 87.7% 59.8% 3 of 59
Operating margin Profitability -4878.9% -5.9% 64 of 67
Net margin Profitability -4620.9% -7.3% 72 of 75
Free-cash-flow margin Cash generation -1929.5% 10.1% 70 of 74
Stock pay as % of revenue Cash generation 257.1% 3.6% 65 of 69
Long-term debt as % of assets Balance sheet 1.9% 23.8% 8 of 53
Days sales outstanding Balance sheet 171 days 72 days 52 of 59

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$709,081
Institutions reporting
16
Shares held vs prior quarter
▲ 42.5%
Positions opened / closed
4 / 2

Top buyers and sellers, Q2 2026: 9 institutions bought and 6 sold ; the biggest buyer was Susquehanna International Group, LLP (+235K shares) and the biggest seller Geode Capital Management, LLC (−97K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Vanguard Capital Management LLC $178,637 510K 25.2% ▲ 25.1%
Geode Capital Management, LLC $117,237 335K 16.5% ▼ 22.5%
Susquehanna International Group, LLP $82,291 235K 11.6% New
Vanguard Fiduciary Trust Co $69,321 198K 9.8% 0.0%
Citadel Advisors LLC $57,699 165K 8.1% New
HRT Financial LP $46,000 133K 6.5% New
Xtx Topco Ltd $36,680 105K 5.2% ▲ 119.8%
Northern Trust Corp $30,662 88K 4.3% ▲ 530.5%
UBS Group AG $30,070 86K 4.2% ▼ 20.3%
Jane Street Group, LLC $26,506 76K 3.7% ▲ 174.0%
Virtu Financial LLC $17,000 48K 2.4% ▼ 43.5%
Two Sigma Securities, LLC $11,648 33K 1.6% ▼ 8.7%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Scienture Holdings, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around January 11, 2027 estimated from the company's past filing pattern, not announced

  • October 19, 2026
  • August 20, 2026
  • May 22, 2026
  • May 15, 2023
  • March 27, 2023
  • November 7, 2022

Recent SEC filings

Data status

When each part of this page on Scienture Holdings, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Scienture Holdings, Inc. in brief

What does Scienture Holdings, Inc. do?
Scienture Holdings, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is Scienture Holdings, Inc.'s stock ticker?
Scienture Holdings, Inc. trades under the ticker SCNX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Scienture Holdings, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Scienture Holdings, Inc. reported revenue of $821,315, 540.6% higher than a year earlier, according to its SEC filings.
What is Scienture Holdings, Inc.'s free cash flow?
Scienture Holdings, Inc.'s free-cash-flow margin is -1929.5% of revenue over the trailing twelve months, ranking 70 of the 74 pharmaceuticals companies we cover.
Who are Scienture Holdings, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Vanguard Capital Management LLC, Geode Capital Management, LLC and Susquehanna International Group, LLP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Scienture Holdings, Inc.'s market cap?
On November 2, 2026, Scienture Holdings, Inc.'s market capitalisation was about $95.3M and net debt of -$8.2M. Market figures come from third-party market data and may be delayed.
Who are Scienture Holdings, Inc.'s competitors?
In our Pharmaceuticals peer group, the companies closest to Scienture Holdings, Inc. are 60 Degrees Pharmaceuticals, Inc., China SXT Pharmaceuticals, Inc., Lipocine Inc., Nutriband Inc. and Akanda Corp. The side-by-side comparison below sets their revenue, margins and growth against Scienture Holdings, Inc.'s.
When is Scienture Holdings, Inc.'s next earnings date?
Around January 11, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Scienture Holdings, Inc. announces its own schedule.